U.S. FDA declines to approve Vanda's stomach paralysis drug
https://s.yimg.com/ny/api/res/1.2/mbFFF31Lbv1rpdeDUdufag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MA--/https://media.zenfs.com/en/reuters-finance.com/5affe103b4d8e89c51d4e2d9661db0e8
https://finance.yahoo.com/news/u-fda-declines-approve-vandas-115730660.html
Vanda Pharmaceuticals' drug tradipitant, aimed at treating stomach paralysis symptoms, has been declined for approval by the US FDA. The company's shares fell 14% in premarket trading. Tradipitant is a drug licensed from Eli Lilly and is also being studied for motion sickness. The FDA had imposed a partial clinical hold on the drug, preventing trials longer than 12 weeks. The company plans to submit a separate application for the drug to prevent vomiting in motion sickness later this year.